Skip to main content
. 2023 Apr 30;4(2):102273. doi: 10.1016/j.xpro.2023.102273

Figure 1.

Figure 1

Establishment of Sorafenib-resistant HCC cell lines

(A) IC50 values of 14 HCC cell lines: 14 HCC cell lines were treated with increasing doses of Sorafenib, and the IC50 values for cell growth inhibition by Sorafenib were determined.

(B) Schematic representation of the establishment of Sorafenib-resistant derivatives of Huh7 and Hep3B HCC cell lines. Huh7 or Hep3B cells were treated with increasing (for Huh7 is from 0 to 10 μM, for Hep3B is from 0 to 5 μM) or with consistently high (7 μM for Huh7, 5 μM for Hep3B) concentration Sorafenib to establish acquired Sorafenib-resistant cell lines.

(C) IC50 values of Huh7-IR, Huh7-CR and Hep3B-IR and Hep3B-CR. These IC50 values are on the range of Sorafenib’s clinically relevant concentration of 10 μM.